Monofree (Tropicamide)

Tropicamide, the active ingredient in Monofree, is an anticholinergic (muscarinic antagonist) presented as an ophthalmic solution for ocular use. It produces rapid pupil dilation (mydriasis) and temporary paralysis of the ciliary muscle (cycloplegia), facilitating detailed retinal evaluation and certain ocular procedures.

GNH USA supplies Monofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monofree (tropicamide) is employed in ophthalmology to achieve controlled pupil dilation and cycloplegia for diagnostic and therapeutic purposes. - Diagnostic eye examinations: provides mydriasis to allow comprehensive retinal and fundus assessment. - Ocular procedures: induces cycloplegia to temporarily suspend accommodation during laser or surgical interventions. - Pediatric eye assessments: facilitates accurate refraction measurements by immobilizing the eye's focusing ability.

Adverse reactions may occur following ocular administration of tropicamide.

Common Side Effects: - Stinging or burning sensation upon instillation - Transient blurred vision - Photophobia due to enlarged pupil - Mild ocular redness - Temporary increase in intra‑ocular pressure

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, itching) - Severe ocular inflammation or uveitis - Persistent mydriasis lasting several days - Systemic anticholinergic effects (dry mouth, tachycardia) - Acute angle‑closure glaucoma in predisposed individuals

Prior to using Monofree, clinicians should assess patient history and ocular conditions. - Evaluate glaucoma risk: avoid in patients with narrow‑angle glaucoma. - Monitor intra‑ocular pressure: check IOP before and after administration. - Use with caution in children: pediatric eyes may be more sensitive. - Avoid contact with broken skin or mucous membranes. - Store at room temperature: keep in the original container, protect from light and moisture.

Tropicamide may interact with other ocular or systemic agents that affect pupil size or cholinergic activity.

Major Interactions (Avoid): - Concurrent use of other mydriatic agents (e.g., phenylephrine) may cause excessive dilation. - Systemic anticholinergics (e.g., atropine) can increase anticholinergic load and systemic side effects.

Moderate Interactions (Monitor Closely): - Topical ocular anesthetics may enhance corneal absorption. - Beta‑blocker eye drops may alter intra‑ocular pressure control. - Systemic antihistamines or antidepressants may modestly increase pupil size.